Beth N. McLellan, M.D.
Assistant Professor, Department of Medicine (Dermatology)
Director, Division of Dermatology at Jacobi Medical Center, Department of Medicine
Beth McLellan graduated with honors from Northwestern University and attended medical school at Wayne State University where she graduated with Alpha Omega Alpha honors. She completed an internship in Internal Medicine at Loyola University Health System and her Dermatology residency at Henry Ford Health System in Detroit where she also served as Chief Resident.
Dr. McLellan specializes in complex medical Dermatology and has a special interest in Supportive Oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair, and nail-related side effects due to cancer therapies. Dr. McLellan has received a Career Development Award from the Dermatology Foundation to study hair loss in breast cancer patients on hormonal treatments. In addition to hair loss, her research interests include hand foot syndrome and radiation dermatitis.
Dr. McLellan has published numerous articles and textbook chapters related to Supportive Oncodermatology. She is regularly invited to speak at Dermatology and Oncology conferences including the annual meeting of the American Academy of Dermatology, the South Beach Symposium, and the International Symposium for Supportive Care in Cancer.
As part of her committment to treating the patient as a whole person, Dr. McLellan is a founder of the New York Vitiligo Support Group. You can get more information about this group by e-mailing NYVitiligo@gmail.com
Scissors, B, Shwayder, T. Topical clindamycin reproducibly causing tinnitus in a 14-year-old
male, Journal of the American Academy of Dermatology. 2006; 54(5 Suppl):S243-4.
Mossbridge JA, Scissors BN, Wright BA. Learning and generalization on asynchrony and order
tasks at sound offset: Implications for underlying neural circuitry, Learning and Memory. 2008;
Hornyak TJ, Giang S, Guzmán EA, Scissors BN, Tuchinda C, He H, Neville JD, Strickland FM.
Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation.
Pigment Cell Melanoma Research. 2009; 22:307-18.
McLellan B, Kerr HA. Cutaneous toxicities of the multikinase inhibitors sorafenib and
sunitinib. Dermatologic Therapy. 2011; 24:396-400.
McLellan B, Robert C, Lacouture ME. Dermatologic manifestations of skin cancer therapies. In
Rigel: Cancer of the Skin 2nd ed. 2011.
Baum, S, Patel R, McLellan B. Clinicopathologic Challenge: A vascular growth following
radiation therapy for breast carcinoma treatment. JAMA Dermatology. 2013; 149:1341-2.
Mir A, Boyd KP, Meehan SA, McLellan B. Hydroxychloroquine-induced hyperpigmentation.
Dermatol Online J. 2013; 19:20723.
Eungdamrong J, McLellan B. Flagellate erythema. Dermatol Online J. 2013; 19:20716.
Terushkin V, Boyd KP, Patel RR, McLellan B. Primary localized cutaneous amyloidosis.
Dermatol Online J. 2013; 19:20711.
Rose AE, Sagger V, Boyd KP, Patel RR, McLellan B. Livedo Reticularis. Dermatol Online J.
McLellan B, Patel D, Lacouture ME. Epidemiology and burden of disease. In Lacouture:
Dermatological Practices and Principles in Oncology. 2013.
McLellan B. How to recognize and manage hand-foot syndrome due to capecitabine or
doxorubicin. The ASCO Post. 2013; 4.
Miller K, Gorcey, L, McLellan B. Chemotherapy-induced nail changes and hand-foot
syndrome: A review of clinical presentation, pathogenesis, and management. J Amer Acad
Dermatol. Accepted for Publication.
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.